Latest Heptares Therapeutics Ltd Stories

MARTINSRIED and MUNICH, Germany, WELWYN GARDEN CITY, England and BOSTON, February 13, 2013 /PRNewswire/ -- Collaboration Harnesses Heptares' StaRs(R) to Open up New Target Space for Therapeutic Antibodies from MorphoSys' Ylanthia(R) Platform MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, have signed an agreement to discover novel antibody...

WELWYN GARDEN CITY, England and BOSTON, April 25, 2012 /PRNewswire/ -- Review published in Trends in Pharmacological Sciences Heptares Therapeutics, the leading GPCR drug discovery company, announces the recent publication of a major review of the state of the art for GPCR drug discovery and new insights that, for the first time, can be obtained from structural biology. The review has been published online in Trends in Pharmacological Sciences, a Cell...

WELWYN GARDEN CITY, England and BOSTON, Massachusetts, March 20, 2012 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery company, announces that an operating company of Shire PLC (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical development. Adenosine A2A is a G-protein coupled receptor (GPCR)...

WELWYN GARDEN CITY, England and BOSTON, March 15, 2012 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery company, announces that its Chief Business Officer, Barry Kenny, will present overview of the Company at 09:45am CET on Tuesday 20 March 2012 at the 6th Annual BIO-Europe Spring international partnering conference. The presentation will take place in room E107, Level 1. BIO-Europe Spring, which is produced by EBD Group, is taking place at the...

WELWYN GARDEN CITY, England, May 9, 2011 /PRNewswire/ -- - Best-in-Class Candidate With Potential in Treatment of CNS Diseases Heptares Therapeutics today announced it has signed an exclusive option agreement with Shire Pharmaceuticals for a novel adenosine A2A antagonist discovered by Heptares and currently in preclinical development. Adenosine A2A is a G-protein coupled receptor (GPCR) involved in the regulation of dopaminergic pathways in the brain. Recently, inhibition of...

CAMBRIDGE, England, April 11, 2011 /PRNewswire/ -- - Deal Includes GBP4.5 Million Upfront Cash and Equity, Up to GBP60.5 Million in Future Milestone Payments, and Royalties on Product Sales Heptares Therapeutics and Takeda Pharmaceutical Company today announced the formation of a two-year drug discovery collaboration focused on a single G-protein coupled receptor (GPCR) that plays an important role in the pathology of central nervous system disorders. This GPCR has proved...

WELWYN GARDEN CITY, England, October 12 /PRNewswire/ -- - Terms Include up to $200 million in Potential Fees and Milestones Plus Royalties Heptares Therapeutics Ltd, the drug discovery company focused on G-protein-coupled receptor (GPCR) targets, announced today that it has entered into an option agreement with the Novartis Option Fund under which Heptares will apply its proprietary StaR(TM) technology to generate novel drug leads against a nominated, unspecified GPCR target...

LONDON, February 24 /PRNewswire/ -- - Syndicate Comprises Leading Sector Investors Clarus Ventures, MVM Life Science Partners and Novartis Option Fund Heptares Therapeutics Ltd, the drug discovery company focused on drugs targeting G-protein-coupled receptors (GPCRs), announces today it has raised GBP21 million (US$30 million) of equity finance in a successful Series A private round from three blue-chip international venture capital firms. Clarus Ventures led the syndicate,...